Psyence Biomedical Has Selected Empax Center As The Second Trial Site For The Company's Ongoing Phase 2b Trial Of Nature-derived Psilocybin As A Potential Treatment For Adjustment Disorder In Palliative Care
Portfolio Pulse from Benzinga Newsdesk
Psyence Biomedical has chosen Empax Center as the second trial site for its Phase 2b trial of nature-derived psilocybin, aimed at treating adjustment disorder in palliative care.
October 24, 2024 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Psyence Biomedical has expanded its Phase 2b trial for psilocybin treatment by selecting Empax Center as the second trial site, potentially advancing its research and development efforts.
The selection of a second trial site indicates progress in Psyence Biomedical's clinical trial process, which could lead to advancements in their psilocybin treatment research. This development is likely to be viewed positively by investors, as it shows the company's commitment to advancing its product pipeline.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80